SI-BONE, Inc. Reports Financial Results for the First Quarter 2024

Rhea-AI Summary

SI-BONE, Inc. reported financial results for the first quarter of 2024, showing worldwide revenue of $37.9 million, a 16% growth from the prior year. The company's U.S. revenue also increased by 16%, with a gross margin of 79%. SI-BONE is optimistic about revenue growth acceleration, driven by new product launches and market expansion. The company updated its 2024 revenue guidance to $164 million - $166 million, indicating a growth of 18% - 20%.

Positive

• Strong revenue growth of 16% in the first quarter of 2024 compared to the prior year

• Increased U.S. revenue by 16% with a gross margin of 79%

• Optimistic outlook for revenue growth acceleration through product launches and market expansion

• Updated 2024 revenue guidance increased to $164 million - $166 million, implying growth of 18% - 20%

Negative

• Operating expenses increased by 10% in the first quarter of 2024

• Operating loss increased by 7% compared to the same period in 2023

• Gross margin decreased to 79% in the first quarter of 2024 due to procedure and product mix impacts

• Net loss improved slightly by 2%, but adjusted EBITDA remained nearly flat year-over-year

Financial Analyst

SI-BONE, Inc.'s recent financial disclosure indicates a promising start to 2024, with a reported worldwide revenue growth of approximately 16% compared to the previous year. The increase in annual guidance to $164 million - $166 million, representing an 18% - 20% growth, suggests a positive trajectory in the company's financial performance. Particularly noteworthy is the company's strong cash position, with $157.8 million in cash and equivalents, which speaks to healthy liquidity that can support ongoing operations and strategic initiatives.

A slight contraction in gross margin from 82% to 79% may raise some concerns regarding cost management and pricing strategy, particularly in light of increased operating expenses, which grew by 10%. Investors should monitor whether the margin compression is a temporary fluctuation due to product mix or indicative of a longer-term trend. Furthermore, the pursuit of an adjusted EBITDA breakeven point is an important milestone for the company, aligning with prudent financial management and long-term sustainability.

Medical Device Market Analyst

The surgical solution sector, where SI-BONE operates, is characterized by high competitive intensity and constant innovation. SI-BONE's strategic move to release a smaller diameter iFuse Bedrock Granite implant is a significant development, likely expanding the company's market share within the pelvic fixation market. The continuation of the New Technology Add-on Payment (NTAP) at $9,828 per case under the CMS FY2024 proposed IPPS Rule provides additional financial incentives for hospitals to adopt this technology. As such, the company's top-line growth is not only a reflection of current demand but also of its strategic positioning for future market penetration.

Moreover, surpassing over 100,000 procedures by more than 3,700 surgeons signals strong adoption rates and widespread clinical acceptance. This market penetration level could serve as a solid foundation for future growth, especially as the company explores adjacent markets. For investors, the increased adoption and expanding product line could signify a favorable long-term outlook, provided the company continues to manage its operational costs effectively.

Annual guidance increased to $164 million - $166 million, implying annual growth of ~18% - 20%

SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended March 31, 2024.

First Quarter 2024 Financial Highlights (all comparisons are to the prior year period)

• Worldwide revenue of $37.9 million, representing growth of ~16%
• U.S. revenue of $35.4 million, representing growth of ~16%
• Gross margin of ~79%
• Over 1,100 U.S. active physicians, representing an increase of ~16%
• Strong liquidity with $157.8 million in cash and equivalents
  

Recent Operational Highlights

• Completed the first pelvic fixation procedure with smaller diameter iFuse Bedrock Granite implant in April
• Continuation of NTAP for iFuse Bedrock Granite at $9,828 per case under CMS FY2024 proposed IPPS Rule
• Surpassed 100,000 procedures performed by over 3,700 surgeons worldwide since inception
  

"I am pleased with the solid start to the year as we continued to benefit from robust procedure volumes across all our target markets and maintained our strong procedure ASP,” said Laura Francis, Chief Executive Officer. “I am confident about our revenue growth acceleration, catalyzed by expansion of our opportunity in the pelvic fixation market with the rollout of the smaller diameter Granite implant and building on the success of iFuse 3D with the adoption of TORQ across all our call points. This top-line growth will also allow us to make significant progress towards our adjusted EBITDA breakeven goal.”

First Quarter 2024 Financial Results

Worldwide revenue was $37.9 million in the first quarter 2024, a ~16% increase from $32.7 million in the corresponding period in 2023. U.S. revenue for the first quarter 2024 was $35.4 million, a ~16% increase from $30.5 million in the corresponding period in 2023. International revenue growth for the first quarter 2024 was $2.4 million compared to $2.3 million in the corresponding period in 2023.

Gross margin was ~79% for the first quarter 2024, as compared to ~82% in the corresponding period in 2023. Gross margin in the first quarter 2024 was impacted by procedure and product mix.

Operating expenses increased ~10% to $41.9 million in the first quarter 2024, as compared to $38.1 million in the corresponding period in 2023. The change in operating expenses was primarily driven by increases in commission related to revenue growth, research and development investments, as well as higher stock based compensation. Operating expenses were also impacted by the timing of our global sales meeting, which was held in the first quarter of 2024 compared to in the second quarter of 2023.

Operating loss increased by ~7% to $12.0 million in the first quarter 2024, as compared to an operating loss of $11.3 million in the corresponding period in 2023.

Net loss improved by ~2%, to $10.9 million, or $0.27 per diluted share for the first quarter 2024, as compared to a net loss of $11.1 million, or $0.32 per diluted share in the corresponding period in 2023.

Adjusted EBITDA loss in the first quarter of 2024 was nearly flat compared to the corresponding period in 2023 at $4.0 million.

Cash and marketable securities were $157.8 million and borrowings were $36.1 million as of March 31, 2024.

2024 Updated Financial Guidance

SI-BONE is updating 2024 worldwide revenue guidance to be in the range of $164 million to $166 million, an increase from the previous guidance of $162 million to $165 million. Compared to 2023, the updated guidance translates to growth of ~18% to ~20%, versus growth of ~17% to ~19% implied in the earlier guidance.

Webcast Information

SI-BONE will host a conference call to discuss the first quarter 2024 financial results after market close on Monday, November 6, 2023 at 4:30 P.M. Eastern Time. The conference call can be accessed live over webcast at https://edge.media-server.com/mmc/p/xs5x4tbm. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.

About SI-BONE, Inc.

SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 3,700 surgeons in performing a total of over 100,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 120 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation and pelvic trauma.

For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

iFuse Bedrock Granite, iFuse-TORQ and SI-BONE are registered trademarks of SI-BONE, Inc. ©2024 SI-BONE, Inc. All Rights Reserved.

Forward Looking Statements

The statements in this press release regarding expectations of future events or results, including SI-BONE’s expectations of continued revenue and procedure growth and financial outlook, contained in this press release are "forward-looking" statements. These forward-looking statements are based on SI-BONE's current expectations and inherently involve significant risks and uncertainties. These risks include SI-BONE's ability to introduce and commercialize new products and indications, SI-BONE's ability to maintain favorable reimbursement for procedures using its products, the impact of any future economic weakness on the ability and desire of patients to undergo elective procedures including those using SI-BONE's devices, SI-BONE's ability to manage risks to its supply chain, future capital requirements driven by new surgical systems requiring instrument tray and implant inventory investment, and the pace of the re-normalization of the healthcare operating environment including the ability and desire of patients and physicians to undergo and perform procedures using SI-BONE's devices. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these and other risks and uncertainties, many of which are described in the company's most recent filing on Form 10-K, and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov), especially under the caption "Risk Factors." SI-BONE does not undertake any obligation to update forward-looking statements and expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, except as required by law.

Use of Non-GAAP Financial Measures

SI-BONE uses adjusted EBITDA, a non-GAAP financial measures that excludes from net loss the effects of interest income, interest expense, depreciation and amortization and stock-based compensation. SI-BONE believes the presentation of adjusted EBITDA is useful to management because it allows management to more consistently analyze period-to-period financial performance and provides meaningful supplemental information with respect to core operational activities used to evaluate management's performance. SI-BONE also believes the presentation of adjusted EBITDA is useful to investors and other interested persons as it enables these persons to use this additional information to assess the company’s performance in using this additional metric that management uses to assess the company’s performance.

Adjusted EBITDA should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because adjusted EBITDA excludes the effect of items that increase or decrease SI-BONE's reported results of operations, management strongly encourages investors to review, when they become available, the company's consolidated financial statements and publicly filed reports in their entirety. The company's definition of adjusted EBITDA may differ from similarly titled measures used by others.

Investor Contact

Saqib Iqbal
Sr. Director, FP&A and Investor Relations
investors@SI-BONE.com

SI-BONE, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except share and per share amounts) (Unaudited)
	Three Months Ended March 31,
		2024				2023
Revenue	$	37,867			$	32,708
Cost of goods sold		8,002				5,924
Gross profit		29,865				26,784
Operating expenses:
Sales and marketing		29,387				27,313
Research and development		4,345				3,291
General and administrative		8,176				7,473
Total operating expenses		41,908				38,077
Loss from operations		(12,043	)			(11,293	)
Interest and other income (expense), net:
Interest income		2,113				932
Interest expense		(881	)			(838	)
Other income (expense), net		(93	)			74
Net loss	$	(10,904	)		$	(11,125	)
Net loss per share, basic and diluted	$	(0.27	)		$	(0.32	)
Weighted-average number of common shares used to compute basic and diluted net loss per share		40,934,392				34,916,106

SI-BONE, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited)
	March 31, 2024				December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents	$	32,040			$	33,271
Short-term investments		125,782				132,748
Accounts receivable, net		22,109				21,953
Inventory		21,049				20,249
Prepaid expenses and other current assets		2,647				3,173
Total current assets		203,627				211,394
Property and equipment, net		17,348				16,000
Operating lease right-of-use assets		2,415				2,706
Other non-current assets		323				325
TOTAL ASSETS	$	223,713			$	230,425
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	7,661			$	4,588
Accrued liabilities and other		11,767				17,452
Operating lease liabilities, current portion		1,433				1,416
Total current liabilities		20,861				23,456
Long-term borrowings		36,107				36,065
Operating lease liabilities, net of current portion		1,192				1,511
Other long-term liabilities		16				18
TOTAL LIABILITIES		58,176				61,050
Stockholders' Equity:
Common stock and additional paid-in capital		576,616				569,481
Accumulated other comprehensive income		266				335
Accumulated deficit		(411,345	)			(400,441	)
TOTAL STOCKHOLDERS’ EQUITY		165,537				169,375
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$	223,713			$	230,425

SI-BONE, INC. RECONCILIATION OF NET LOSS TO NON-GAAP ADJUSTED EBITDA (In thousands) (unaudited)
		Three Months Ended March 31,
			2024				2023
Net loss		$	(10,904	)		$	(11,125	)
Interest income			(2,113	)			(932	)
Interest expense			881				838
Depreciation and amortization			1,089				1,086
Stock-based compensation			7,030				6,194
Adjusted EBITDA		$	(4,017	)		$	(3,939	)

FAQ

What was SI-BONE, Inc.'s worldwide revenue for the first quarter of 2024?

SI-BONE, Inc. reported worldwide revenue of $37.9 million for the first quarter of 2024, showing a 16% growth from the prior year.

How much was the U.S. revenue growth for SI-BONE, Inc. in the first quarter of 2024?

SI-BONE, Inc. experienced a 16% growth in U.S. revenue in the first quarter of 2024, with a gross margin of 79%.

What is SI-BONE, Inc.'s updated 2024 revenue guidance?

SI-BONE, Inc. updated its 2024 revenue guidance to $164 million - $166 million, indicating a growth of 18% - 20%.

What was the impact of operating expenses on SI-BONE, Inc. in the first quarter of 2024?

Operating expenses increased by 10% in the first quarter of 2024 for SI-BONE, Inc.

How did SI-BONE, Inc.'s net loss change in the first quarter of 2024 compared to the same period in 2023?

SI-BONE, Inc.'s net loss improved by 2% in the first quarter of 2024, with a loss of $10.9 million or $0.27 per diluted share.